Skip to main content

Table 2 Distribution of cell cycle phases in vehicle-treated and ABT-737-treated thyroid carcinoma cells (24 h, 1 µM)

From: The BH3 mimetic drug ABT-737 induces apoptosis and acts synergistically with chemotherapeutic drugs in thyroid carcinoma cells

Cell line

Treatment

% subG1

% G1

% G2/M

% S

ML1 (FTC)

Untreated

0.39 ± 0.1

37.5 ± 2.1

30.5 ± 2.4

32.0 ± 2.2

24 h ABT-737

21.2 ± 2.9*

34.0 ± 3.1

21.5 ± 1.9*

44.5 ± 3.6*

FTC236 (FTC)

Untreated

0.21 ± 0.1

48.5 ± 4.4

24.1 ± 1.6

27.4 ± 2.0

24 h ABT-737

18.8 ± 2.0*

41.6 ± 3.9

20.3 ± 2.6

38.1 ± 2.9*

BHT101 (PTC)

Untreated

3.16 ± 2.8

65.1 ± 5.3

16.0 ± 1.7

18.9 ± 2.3

24 h ABT-737

54.8 ± 4.6*

42.6 ± 5.3*

16.1 ± 2.7

41.3 ± 5.0*

SW1736 (ATC)

Untreated

1.52 ± 0.4

54.9 ± 5.4

15.2 ± 2.2

29.9 ± 2.6

24 h ABT-737

39.9 ± 5.9*

42.8 ± 4.5*

13.2 ± 1.2

44.0 ± 3.6*

HTh7 (ATC)

Untreated

3.10 ± 0.2

60.1 ± 4.9

10.6 ± 0.8

29.3 ± 2.6

24 h ABT-737

11.1 ± 1.4*

59.6 ± 4.7

3.3 ± 0.4*

37.1 ± 2.6*

  1. Values for G1-, G2/M- and S-phase are determined for the living cells that were not included in the sub-G1-peak
  2. * Indicates significant change (p < 0.05, Student’s t test) compared to controls treated with vehicle